{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,4,16]],"date-time":"2024-04-16T02:07:10Z","timestamp":1713233230458},"reference-count":20,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,9,13]]},"DOI":"10.7759\/cureus.45180","type":"journal-article","created":{"date-parts":[[2023,9,14]],"date-time":"2023-09-14T00:25:56Z","timestamp":1694651156000},"source":"Crossref","is-referenced-by-count":1,"title":["A Case of Prolonged Recovery for Post-percutaneous Coronary Intervention (PCI) Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitor-Induced Euglycemic Diabetic Ketoacidosis in a 28-Year-Old"],"prefix":"10.7759","author":[{"given":"Cyrena","family":"Petersen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frederick","family":"Gyabaah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jose","family":"Sotelo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandeesh","family":"Yohanna","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abhizith","family":"Deoker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.2174\/1573399812666160421121307","article-title":"Euglycemic diabetic ketoacidosis: a review","volume":"13","author":"Modi A","year":"2017","unstructured":"Modi A, Agrawal A, Morgan F. Euglycemic diabetic ketoacidosis: a review. Curr Diabetes Rev. 2017, 13:315-21. 10.2174\/1573399812666160421121307","journal-title":"Curr Diabetes Rev"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejim.2019.03.014","article-title":"Euglycemic diabetic ketoacidosis","volume":"63","author":"Barski L","year":"2019","unstructured":"Barski L, Eshkoli T, Brandstaetter E, Jotkowitz A. Euglycemic diabetic ketoacidosis. Eur J Intern Med. 2019, 63:9-14. 10.1016\/j.ejim.2019.03.014","journal-title":"Eur J Intern Med"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1002\/dmrr.2924","article-title":"Ketoacidosis associated with SGLT2 inhibitor treatment: analysis of FAERS data","volume":"33","author":"Blau JE","year":"2017","unstructured":"Blau JE, Tella SH, Taylor SI, Rother KI. Ketoacidosis associated with SGLT2 inhibitor treatment: analysis of FAERS data. Diabetes Metab Res Rev. 2017, 33:e2924. 10.1002\/dmrr.2924","journal-title":"Diabetes Metab Res Rev"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1007\/s11892-017-0874-3","article-title":"SGLT2-I in the hospital setting: diabetic ketoacidosis and other benefits and concerns","volume":"17","author":"Levine JA","year":"2017","unstructured":"Levine JA, Karam SL, Aleppo G. SGLT2-I in the hospital setting: diabetic ketoacidosis and other benefits and concerns. Curr Diab Rep. 2017, 17:54. 10.1007\/s11892-017-0874-3","journal-title":"Curr Diab Rep"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1089\/dia.2018.0081","article-title":"Combined SGLT1 and SGLT2 inhibitors and their role in diabetes care","volume":"20","author":"Danne T","year":"2018","unstructured":"Danne T, Biester T, Kordonouri O. Combined SGLT1 and SGLT2 inhibitors and their role in diabetes care. Diabetes Technol Ther. 2018, 20:S269-77. 10.1089\/dia.2018.0081","journal-title":"Diabetes Technol Ther"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01536-x","article-title":"The SGLT2 inhibitor dapagliflozin in heart failure with preserved ejection fraction: a multicenter randomized trial","volume":"27","author":"Nassif ME","year":"2021","unstructured":"Nassif ME, Windsor SL, Borlaug BA, et al.. The SGLT2 inhibitor dapagliflozin in heart failure with preserved ejection fraction: a multicenter randomized trial. Nat Med. 2021, 27:1954-60. 10.1038\/s41591-021-01536-x","journal-title":"Nat Med"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1111\/jdi.12401","article-title":"Euglycemic diabetic ketoacidosis induced by SGLT2 inhibitors: possible mechanism and contributing factors","volume":"7","author":"Ogawa W","year":"2016","unstructured":"Ogawa W, Sakaguchi K. Euglycemic diabetic ketoacidosis induced by SGLT2 inhibitors: possible mechanism and contributing factors. J Diabetes Investig. 2016, 7:135-8. 10.1111\/jdi.12401","journal-title":"J Diabetes Investig"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-89752-w","article-title":"SGLT-2 inhibitors associated euglycemic and hyperglycemic DKA in a multicentric cohort","volume":"11","author":"Ata F","year":"2021","unstructured":"Ata F, Yousaf Z, Khan AA, et al.. SGLT-2 inhibitors associated euglycemic and hyperglycemic DKA in a multicentric cohort. Sci Rep. 2021, 11:10293. 10.1038\/s41598-021-89752-w","journal-title":"Sci Rep"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2016.11.002","article-title":"SGLT2 inhibitor-associated diabetic ketoacidosis: clinical review and recommendations for prevention and diagnosis","volume":"38","author":"Goldenberg RM","year":"2016","unstructured":"Goldenberg RM, Berard LD, Cheng AY, Gilbert JD, Verma S, Woo VC, Yale JF. SGLT2 inhibitor-associated diabetic ketoacidosis: clinical review and recommendations for prevention and diagnosis. Clin Ther. 2016, 38:2654-2664.e1. 10.1016\/j.clinthera.2016.11.002","journal-title":"Clin Ther"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1007\/s13340-020-00473-3","article-title":"COVID-19-associated euglycemic diabetic ketoacidosis in a patient with type 2 diabetes on SGLT2 inhibitor: a case report","volume":"12","author":"Batista DV","year":"2021","unstructured":"Batista DV, Vieira CA, Costa TA, Lima EG. COVID-19-associated euglycemic diabetic ketoacidosis in a patient with type 2 diabetes on SGLT2 inhibitor: a case report. Diabetol Int. 2021, 12:313-6. 10.1007\/s13340-020-00473-3","journal-title":"Diabetol Int"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.amsu.2022.104879","article-title":"Empagliflozin induced euglycemic diabetic ketoacidosis. A case reports","volume":"84","author":"Altowayan WM","year":"2022","unstructured":"Altowayan WM. Empagliflozin induced euglycemic diabetic ketoacidosis. A case reports. Ann Med Surg (Lond). 2022, 84:104879. 10.1016\/j.amsu.2022.104879","journal-title":"Ann Med Surg (Lond)"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.aace.2020.11.009","article-title":"Euglycemic diabetic ketoacidosis caused by SGLT2 inhibitors and a ketogenic diet: a case series and review of literature","volume":"7","author":"Mistry S","year":"2021","unstructured":"Mistry S, Eschler DC. Euglycemic diabetic ketoacidosis caused by SGLT2 inhibitors and a ketogenic diet: a case series and review of literature. AACE Clin Case Rep. 2021, 7:17-9. 10.1016\/j.aace.2020.11.009","journal-title":"AACE Clin Case Rep"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1155\/2020\/8832833","article-title":"A case of diabetic ketoacidosis in a patient on an SGLT2 inhibitor and a ketogenic diet: a critical trio not to be missed","volume":"2020","author":"Steinmetz-Wood S","year":"2020","unstructured":"Steinmetz-Wood S, Gilbert M, Menson K. A case of diabetic ketoacidosis in a patient on an SGLT2 inhibitor and a ketogenic diet: a critical trio not to be missed. Case Rep Endocrinol. 2020, 2020:8832833. 10.1155\/2020\/8832833","journal-title":"Case Rep Endocrinol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-020-03051-3","article-title":"Predisposing factors for the development of diabetic ketoacidosis with lower than anticipated glucose levels in type 2 diabetes patients on SGLT2-inhibitors: a review","volume":"77","author":"Bamgboye AO","year":"2021","unstructured":"Bamgboye AO, Oni IO, Collier A. Predisposing factors for the development of diabetic ketoacidosis with lower than anticipated glucose levels in type 2 diabetes patients on SGLT2-inhibitors: a review. Eur J Clin Pharmacol. 2021, 77:651-7. 10.1007\/s00228-020-03051-3","journal-title":"Eur J Clin Pharmacol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.4103\/jfmpc.jfmpc_644_21","article-title":"Euglycemic diabetic ketoacidosis associated with SGLT2 inhibitors: a systematic review and quantitative analysis","volume":"11","author":"Dutta S","year":"2022","unstructured":"Dutta S, Kumar T, Singh S, Ambwani S, Charan J, Varthya SB. Euglycemic diabetic ketoacidosis associated with SGLT2 inhibitors: a systematic review and quantitative analysis. J Family Med Prim Care. 2022, 11:927-40. 10.4103\/jfmpc.jfmpc_644_21","journal-title":"J Family Med Prim Care"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/j.aace.2020.11.014","article-title":"AA case of SGLT2 inhibitor-associated euglycemic diabetic ketoacidosis following coronary artery bypass surgery","volume":"7","author":"Osafehinti DA","year":"2021","unstructured":"Osafehinti DA, Okoli OJ, Karam JG. AA case of SGLT2 inhibitor-associated euglycemic diabetic ketoacidosis following coronary artery bypass surgery. AACE Clin Case Rep. 2021, 7:20-2. 10.1016\/j.aace.2020.11.014","journal-title":"AACE Clin Case Rep"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.10878","article-title":"Euglycemic diabetic ketoacidosis with sodium-glucose cotransporter-2 inhibitor use post-bariatric surgery: a brief review of the literature","volume":"12","author":"Iqbal QZ","year":"2020","unstructured":"Iqbal QZ, Mishiyev D, Zia Z, Ruggiero RA, Aftab G. Euglycemic diabetic ketoacidosis with sodium-glucose cotransporter-2 inhibitor use post-bariatric surgery: a brief review of the literature. Cureus. 2020, 12:e10878. 10.7759\/cureus.10878","journal-title":"Cureus"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/j.eprac.2022.06.006","article-title":"Inpatient perioperative euglycemic diabetic ketoacidosis due to sodium-glucose cotransporter-2 inhibitors - lessons from a case series and strategies to decrease incidence","volume":"28","author":"Mehta PB","year":"2022","unstructured":"Mehta PB, Robinson A, Burkhardt D, Rushakoff RJ. Inpatient perioperative euglycemic diabetic ketoacidosis due to sodium-glucose cotransporter-2 inhibitors - lessons from a case series and strategies to decrease incidence. Endocr Pract. 2022, 28:884-8. 10.1016\/j.eprac.2022.06.006","journal-title":"Endocr Pract"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.4103\/sjmms.sjmms_478_19","article-title":"Management of diabetic ketoacidosis in adults: a narrative review","volume":"8","author":"Eledrisi MS","year":"2020","unstructured":"Eledrisi MS, Elzouki AN. Management of diabetic ketoacidosis in adults: a narrative review. Saudi J Med Med Sci. 2020, 8:165-73. 10.4103\/sjmms.sjmms_478_19","journal-title":"Saudi J Med Med Sci"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1530\/EDM-19-0087","article-title":"Prolonged acidosis is a feature of SGLT2i-induced euglycaemic diabetic ketoacidosis","volume":"2019","author":"Rafey MF","year":"2019","unstructured":"Rafey MF, Butt A, Coffey B, Reddington L, Devitt A, Lappin D, Finucane FM. Prolonged acidosis is a feature of SGLT2i-induced euglycaemic diabetic ketoacidosis. Endocrinol Diabetes Metab Case Rep. 2019, 2019:10.1530\/EDM-19-0087","journal-title":"Endocrinol Diabetes Metab Case Rep"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/160310-a-case-of-prolonged-recovery-for-post-percutaneous-coronary-intervention-pci-sodium-glucose-cotransporter-2-sglt2-inhibitor-induced-euglycemic-diabetic-ketoacidosis-in-a-28-year-old","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T20:04:51Z","timestamp":1707509091000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/160310-a-case-of-prolonged-recovery-for-post-percutaneous-coronary-intervention-pci-sodium-glucose-cotransporter-2-sglt2-inhibitor-induced-euglycemic-diabetic-ketoacidosis-in-a-28-year-old"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,13]]},"references-count":20,"URL":"https:\/\/doi.org\/10.7759\/cureus.45180","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2023,9,13]]}}}